These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29969918)

  • 1. Validation Master Plans: Progress of Implementation in the Pharmaceutical Industry.
    Elser C; Richmond FJ
    Ther Innov Regul Sci; 2019 May; 53(3):354-363. PubMed ID: 29969918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
    Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking control: the Validation Master Plan.
    Donawa ME
    Med Device Technol; 1995 Dec; 6(10):12-4. PubMed ID: 10158118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standalone Regulatory Agreements for Product-Development Collaborations in the Medical Products Industry.
    Wilhelm ME; Pire-Smerkanich N; Richmond FJ
    Ther Innov Regul Sci; 2024 Sep; 58(5):897-909. PubMed ID: 38822181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive Manufacturing with 3D Printing: Progress from Bench to Bedside.
    Rahman Z; Barakh Ali SF; Ozkan T; Charoo NA; Reddy IK; Khan MA
    AAPS J; 2018 Sep; 20(6):101. PubMed ID: 30209693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?
    Gauvin DV; Zimmermann ZJ; Kallman MJ
    Drug Alcohol Depend; 2016 Nov; 168():307-319. PubMed ID: 27629024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
    Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
    Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Regulatory Landscape.
    Matsuda Y
    AAPS PharmSciTech; 2018 Dec; 20(1):2. PubMed ID: 30560302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current good manufacturing practice: proposed revision of certain requirements for finished pharmaceuticals; proposed rule, May 3, 1996 (61 FR 20103), [Docket No. 95N-0362]. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1996; 50(6):346-51. PubMed ID: 9038078
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.